Inhalation Sciences receives new order worth 196 KEURO from University of Vienna

(Stockholm, 17 November 2020) The Department of Pharmaceutical Technology and Biopharmaceutics at the University of Vienna carries out highly innovative research into new micro and nano formulations of pharmaceuticals. It has now ordered PreciseInhale®, ISAB’s high-precision aerosol R&D system, plus its Nose-Only and the unique Intratracheal Exposure Modules. The total order is worth 196 KEURO.

Both of the in vivo modules that the Department ordered employ Precision Dosing - PreciseInhale’s unique one-animal-at-a-time methodology – which delivers exceptionally precise, competitive lung data from all regions of the lung. With Precision Dosing, researchers can tailor the exact dose from a gentle, highly controllable stream of aerosol, unlike the conventional high-pressure jet of aerosol used in standard technologies.

The intratracheal in vivo module chosen is unique in pre-clinical lung research. It is highly lung-specific, bypassing the animal’s nasal cavity in a more clinical-like way. The constant monitoring of aerosol concentration and of the animal’s breathing pattern throughout the experiment, generates data of world- leading precision, with a typical Standard Deviation of less than 10%.

Prof. Dr. Lea Ann Dailey, Head of the Department of Pharmaceutical Technology and Biopharmaceutics: “In the academic research setting we often face the challenge of working with limited amounts of novel materials. The high dosing precision and reduced material requirements of the PreciseInhale® System will enable us to generate full pharmacokinetic and toxicokinetic data sets with the limited amount of material we have available. It is ideal for our research needs.“

ISAB CEO Manoush Masarrat: “We’re delighted to welcome the team from the University of Vienna as highly-valued customers. We have long experience of some of the exciting research areas they work in, from nano-particle exposure to preclinical cell-culturing models simulating the conditions in the lung. We’re proud that a customer of such tremendous expertise has chosen us and look forward to seeing the results they achieve as they move forward with PreciseInhale®.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for aerosol generation and inhalation research. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on November 11, 2020 at 0915 CET.

Tags: